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Introduction
Age-related macular degeneration (ARMD), the leading cause of 
vision loss in industrialized nations (1), affects 30 to 50 million 
people worldwide, but this is predicted to rise to 288 million by 
2040 (2). There are 2 forms of ARMD, neovascular (wet) and atro-
phic (dry). Both show changes in the outer retina and can coexist 
in the same eye. Normally, retinal pigment epithelial (RPE) cells 
secrete VEGF, which has autocrine trophic effects (3), supports 
photoreceptors and, after crossing Bruch’s membrane, maintains 
the extraretinal vasculature of the fenestrated choriocapillaris (4). 
In dry ARMD, there can be subretinal deposits called drusen, pho-
toreceptor dysfunction, RPE atrophy, and choriocapillaris degen-
eration, together called geographic atrophy (GA) (5). There is no 
treatment for GA. Wet ARMD is characterized by drusen, choroi-
dal neovascularization (CNV), and retinal edema (1). High con-
centrations of VEGF contribute to CNV development (6), so wet 
ARMD is treated with intravitreal anti-VEGF injections. This ther-
apy revolutionized ARMD patient care. While it does not reverse 
CNV, it does decrease macular edema that leads to reduced visual 
acuity. However, not all patients respond equally. Over 40% have 
stable or improved visual acuity (7), but 10%–30% of patients 
treated develop reduced visual acuity with regular repeated injec-
tions over time (8, 9). This could be due to the loss of VEGF’s tro-
phic effects (4, 10). Mice develop choriocapillaris degeneration 
and photoreceptor dysfunction 3 days after genetic ablation of 
RPE-derived VEGF (4), while primates given intravitreal VEGF 
antagonists showed reduced thickness and number of fenestra-
tions of the choriocapillaris maximal 4 days after treatment (11–
13). This recovered 2 weeks later. Furthermore, cell culture studies 
suggested anti-VEGF agents cause RPE dedifferentiation (14), 
reduced barrier function (15), permeability (16), and impaired 
phagocytosis (17), but have no effect on apoptosis (18). There-
fore, complete VEGF inhibition may be detrimental, but given 
the variability in reported effects, modifying factors could influ-
ence patient response and risk of developing side effects. A recent 
meta-analysis combining 13 studies reported reduced response to 
anti-VEGF therapy in patients homozygous for the complement 
factor H (CFH) polymorphism Y402H (19). The reason why these 
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lar CFH staining (Figure 1A, controls shown in Supplemental Fig-
ure 1, A–C; supplemental material available online with this article; 
doi:10.1172/JCI86418DS1), and glomerular deposits of C3 that 
were suggestive of complement activity (Figure 1B). To further 
examine these results, human glomerular endothelial cells and 
podocytes were studied and were shown to synthesize inhibitory 
CFH in response to VEGF in a dose-dependent manner (Figure 1C). 
The production of CFH was confirmed by Western blotting (Fig-
ure 1D, cell lysate; Figure 1E, condition media) and by quantitative 
PCR (qPCR) using CFH-specific primers (Figure 1F). VEGF did not 
have this effect on CFH in other endothelial and control cell lines, 
suggesting the observations were specific to the glomerular cells 
(Figure 1C, HUVEC and HEK293 panels). Furthermore, 24 hours of 
VEGF pretreatment reduced complement deposition on these cells 
after in vitro complement activation (Figure 1G). This suggests that 
the VEGF-induced changes were functionally relevant.
CFH is considered the most important inhibitor of the alter-
native pathway (30). To determine why VEGF also reduced C4/
C4d deposition (Supplemental Figure 1, D and E), we studied oth-
er complement regulators. In the glomeruli of mice with inducible, 
podocyte-specific Vegfa deletion, CD59a was also reduced, but 
CD55 and Crry were not (Supplemental Figure 1, F–H). CD46 was 
not examined in mice, since it is only expressed in the testes (31). 
Human glomerular endothelial cells expressed more CD59 and 
CD46, but not CD55, after VEGF treatment (Supplemental Figure 
1, I–K). These effects were dose dependent.
Similarly, in primary human RPE cells, VEGF caused a 
dose-dependent increase of CFH and CD46, but not CD55 (Figure 
2, A–C and Supplemental Figure 2, A and B), with reduced comple-
ment deposits (Figure 2D and Supplemental Figure 2C). The same 
results were obtained from ARPE19 cells, but only primary human 
RPE cell data are shown here. VEGF antagonism using bevaci-
zumab or the fab fragment ranibizumab reduced CFH and CD46 
expression (Figures 2, A–C and Supplemental Figure 2, A and B) 
and increased C3d and C4d deposits (Figure 2D and Supplemen-
tal Figure 2C). The doses of VEGF antagonist used were compa-
rable to those given to patients by intravitreal injection. To deter-
mine whether these effects also occurred in vivo, RPE-induced 
Vegfa knockout was accomplished in adult mice using VMD2-Cre. 
These mice showed severe choriocapillaris attenuation (4) and, 
similarly to mice with inducible, podocyte-specific Vegfa, comple-
ment inhibitors CFH and CD59a were reduced 3 days after induc-
tion (Figure 2, E and F, and Supplemental Figure 2D). Reduction in 
VEGF was confirmed in choroid/RPE sections from RPE-induced 
Vegfa-knockout mice (Figure 2G). These same sections showed 
increased C5b-9 levels compared with controls, showing that they 
had increased complement activation (Figure 2H). Conversely, 
3 days after RPE-induced Vhl knockout, which causes pseudo- 
hypoxia and increased RPE-derived VEGF (32), more CFH was 
detected (Supplemental Figure 2E). These effects were not limit-
ed to the outer retina. Other sources of retinal VEGF are amacrine 
and horizontal cells, lateral interneurons that associate with intra-
retinal capillaries (10). When Vegfa and Vhl were knocked out of 
these neurons, similar changes in CFH were detected in the inner 
retina, showing an in vivo dose response (Supplemental Figure 
2, F and G). Reductions in CD55 and CD59a, but not Crry, were 
also noted in these mice (Supplemental Figure 2H). These results 
patients respond less well is unclear, but could suggest a relation-
ship between VEGF and complement. This is supported by reports 
that choriocapillaris endothelial cell loss is an early feature of 
ARMD (20, 21) and that this is associated with increased deposi-
tion of complement membrane attack complexes (MACs) (21, 22).
Complement activation is evident in both types of ARMD, 
including GA, with complement deposits detected in drusen, on 
RPE cells, Bruch’s membrane, and the choriocapillaris (23, 24). 
The complement system is composed of over 30 proteins and can 
be activated by 3 pathways: the classical, lectin, and alternative 
pathways (25). Each pathway results in the formation of a C3 con-
vertase, which hydrolyses C3 to C3a and C3b, and a C5 conver-
tase, which cleaves C5 to C5a and C5b. C5 combines with C6-9, 
forming the MAC (25). Cells express inhibitory proteins that pre-
vent inappropriate complement activation and cellular damage. 
Inhibitors can be membrane bound, like CD59, CD55, CD46 and 
Crry in mice, or circulate like CFH, which functions in serum or 
at the cell surface to stop alternative pathway activation (25). RPE 
cells synthesize CFH (26). From 30% to 50% of ARMD patients 
carry a CFH polymorphism (Y402H) (1, 27) that increases the 
risk of developing ARMD (1) and may predispose to complement 
activation (24). It is not fully understood how this contributes to 
ARMD pathogenesis, but suggests that complement regulation is 
important for the outer retina.
Another organ where VEGF and complement regulation are 
important is the kidney. The glomerular functional unit parallels 
that of the outer retina. The epithelial podocyte, like the RPE cell, 
produces VEGF that crosses the glomerular basement membrane 
and maintains the fenestrated glomerular endothelium. Togeth-
er, these structures form the glomerular filtration barrier. A subtle 
balance of local VEGF production is required for normal glomer-
ular function. Overexpression of podocyte-derived VEGF in the 
glomerulus causes a collapsing glomerulopathy (28), while inhibi-
tion of podocyte VEGF disrupts the filtration barrier, causing pro-
tein leak and glomerular thrombotic microangiopathy (TMA) (29).
Glomerular TMA is also the pathological hallmark of hemolyt-
ic uremic syndrome (HUS) (25), the clinical triad of acute kidney 
injury, microangiopathic hemolytic anemia, and thrombocytope-
nia. A proportion of familial atypical HUS (aHUS) cases result from 
complement protein mutations, particularly CFH (25), which leads 
to overactivation of complement in the glomerulus, causing TMA.
Since both the outer retina and renal glomerulus synthesize 
local VEGF, are sensitive to changes in VEGF, and are vulnera-
ble to genetic variation in CFH and complement activation, we 
hypothesized that VEGF could regulate local complement activity 
by inducing CFH synthesis. Here, we show that reduction in VEGF 
through pharmacological inhibition or genetic ablation decreases 
local CFH and other complement regulators in both the retina 
and renal glomerulus, potentially making these sites vulnerable to 
complement activation.
Results
Genetic VEGF ablation inhibits local CFH synthesis in the kidney and 
eye. To study the effects of reduced VEGF levels on complement, 
glomerular VEGF was ablated in adult mice using a podocyte- 
inducible Cre as previously reported (29). Fourteen days after 
VEGF knockdown, mice developed TMA (29), reduced glomeru-
Downloaded from http://www.jci.org on December  9, 2016.   https://doi.org/10.1172/JCI86418
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3jci.org
Figure 1. VEGF regulates CFH expression in the glomerulus. Adult mice with an induced deletion of podocyte Vegfa showed reduced CFH staining in their 
glomeruli compared with control mice (A, CFH red, podocin green, DAPI blue) and showed glomerular C3 staining (B, C3 green, podocin red, DAPI blue). Human 
GEnC and podocytes stained positively for CFH (red, DAPI blue) under normal cell culture conditions (C, media). This was removed by 0.1 M acetic acid treatment 
(C, after AA). CFH staining recurred after 24 hours in serum-free media (SFM), and this was significantly increased by VEGF treatment in a dose-dependent man-
ner. HUVECs also showed CFH staining, but they showed a different response to VEGF treatment (C). HEK293 cells did not show CFH staining, and there was no 
change with VEGF treatment (C). Immunofluorescent studies were validated using Western blotting of cell lysates (D, n = 4), condition media (E, representative, 
n = 4), and qPCR (F, n = 4) shown for GEnC and podocytes (D and F, n = 4, 1-way ANOVA). Twenty-four hours of VEGF treatment also reduced GEnC and podocyte 
C3d (G) (green, DAPI blue) deposits after cell-surface complement activation. (A and B) n = 8–10/group. 20 glomeruli/animal imaged for each antibody tested 
and averaged. Unpaired, 2-tailed t test. (C and G) Representative images shown from 4 independent experiments. Ten images obtained for each condition. MFI 
was calculated for CFH/C3d and corrected for cell number determined by DAPI-stained nuclei to semi-quantitatively compare expression. One-way ANOVA with 
Bonferroni’s post hoc analysis. Scale bars: 10 μm (A); 50 μm (B, GEnC); 25 μm (B, podocytes); 50 μm (B, HUVEC); 50 μm (B, HEK293); 50 μm (C); 50 μm (G).  
*P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 2. Retinal CFH expression is regulated by VEGF. RPE cells 
showed a dose-dependent increase in CFH protein (red, DAPI blue) 
after VEGF treatment, but this effect was inhibited by VEGF antag-
onism using bevacizumab or the fab fragment ranibizumab (A). 
Quantification of the IF images is shown in the graph. Results were 
validated using Western blotting of cell lysates (B, n = 4) and qPCR 
(C, n = 4). VEGF pretreatment reduced C3d deposits (green, DAPI 
blue) on RPE cells after complement activation, while VEGF antago-
nism by bevacizumab or ranibizumab caused increased complement 
deposits (D). Three days after RPE-induced deletion of Vegfa in adult 
mice, reduced CFH RNA (E, CFH red, DAPI blue, n = 8) was detected 
by in situ hybridization and qPCR (F, n = 3). Dissection of the choroid/
RPE from mutant mice showed a significant reduction in VEGF  
(G, n = 4), but significantly more C5b-9, indicating complement acti-
vation (H, n = 4). (A and D) Representative images from 4 indepen-
dent experiments. Ten images obtained for each condition. MFI was 
measured and corrected for cell number. (A) Two-way ANOVA.  
(D) One-way ANOVA with Bonferroni’s post hoc analysis. GCL, gangli-
on cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale 
bars: 100 μm. *P < 0.05; **P < 0.01; ***P < 0.001; ##P < 0.01;  
###P < 0.001. Statistics comparing media alone with VEGF treat-
ments are shown by asterisks, while statistics showing the effect of 
adding the anti-VEGF agent are shown by hatch marks
Downloaded from http://www.jci.org on December  9, 2016.   https://doi.org/10.1172/JCI86418
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5jci.org
suggest that VEGF regulation 
of CFH and other comple-
ment inhibitors is a common 
mechanism in the retina and 
thus may have implications 
for the pathogenesis of oth-
er retinal diseases, e.g., dia-
betic retinopathy. Further-
more, we showed that VEGF 
reduction in the glomerulus 
or the retina was associated 
with reduced CFH, comple-
ment deposition, and vascu-
lar changes, suggesting that 
local complement regulation 
is important for both these 
sites.
VEGF-induced CFH 
changes are mediated by PKC 
signaling. To begin to exam-
ine the molecular mecha-
nisms underlying the CFH 
expression changes, human 
RPE cells were treated with 
several inhibitors of path-
ways downstream of VEGF/
VEGFR2 signaling (33, 34) 
prior to VEGF stimulation. 
Pharmacological inhibition of 
PKC (GF109203X) and PKA 
(H-89), but not p38 MAPK 
(SB202190), prevented the 
VEGF-induced increase in 
CFH transcript (Figure 3A). 
The reduction was compara-
ble to that produced by beva-
cizumab. Both PKA and PKC 
phosphorylate the transcrip-
tion factor CREB (35), which 
previous studies showed has 
putative responsive elements 
in the human CFH promoter 
(36). CREB phosphorylation 
was shown to be sensitive to 
VEGF supplementation or 
inhibition (Figure 3B). Con-
versely, PKC activation (phor-
bol 12-myristate 13-acetate 
[PMA]) and, to a lesser extent, 
PKA activation (forskolin), 
increased CFH transcripts 
in both podocytes and RPE 
cells (Figure 3C). Podocytes 
were also tested with the PKC 
inhibitor (GF109203X) and 
bevacizumab prior to VEGF 
stimulation, and a reduction in 
Figure 3. VEGF-induced changes in CFH were mediated by PKC signaling via CREB. RPE cells treated with either 
PKC (GF109203X) or PKA inhibitor (H-89) before treatment with VEGF failed to produce an increase in CFH RNA 
transcript when compared with VEGF treatment alone. This was comparable to the effect of bevacizumab and VEGF 
treatment (A, n = 4). Inhibiting p38 MAPK (SB202190) prior to VEGF stimulation had no effect on the increase in 
CFH transcript. VEGF caused greater phosphorylation of the CREB transcription factor (top panel), while anti-VEGF 
treatment reduced this phosphorylation (B, n = 4). Total CREB was also measured in these samples (lower panel). 
Human RPE cells and podocytes treated with the PKC activator (PMA) or PKA/adenylate cyclase activator (forsko-
lin) showed increased CFH transcript compared with control (C, n = 3). The effect was more pronounced with PKC 
activation. Human podocytes were then treated with PKC inhibitor (GF109203X) or bevacizumab prior to VEGF stim-
ulation, and they also showed reduced CFH RNA compared with VEGF treatment alone (D, n = 3). Podocytes with a 
CRISPR-induced knockout of PKC-α showed reduced CREB phosphorylation after VEGF stimulation compared with 
control cells (E, n = 3), showing that podocyte VEGF stimulation produced CREB phosphorylation via PKC-α. Finally, 
podocytes with a CRISPR-induced knockout of CREB showed significantly reduced CFH RNA compared with control 
VEGF–stimulated podocytes (F, n = 3). One-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.
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CFH RNA was detected (Figure 3D). To further examine this mech-
anism, and because the greatest effects were seen with PKC mod-
ulation, a CRISPR/Cas9 PKC-α knockout podocyte cell line was 
made. In contrast to control podocytes, PKC-α knockout reduced 
CREB phosphorylation after VEGF stimulation (Figure 3E), further 
suggesting that VEGF-induced CREB phosphorylation was medi-
ated by PKC-α. Next, we tested podocytes with a CRISPR/Cas9- 
induced CREB knockout and found that, compared with control 
podocytes, these cells produced significantly less CFH RNA after 
VEGF stimulation (Figure 3F). Together, these data suggest that 
the VEGF-induced increase in CFH is mediated via PKC-α/CREB 
signaling. Further work is needed to confirm these results and 
probe further into the mechanisms responsible for the differential 
response observed between endothelial cells.
Intravitreal anti-VEGF injection induced complement activa-
tion in the retina. Having shown that genetic VEGF manipulation 
altered CFH expression, we sought to determine whether pharma-
cological VEGF reduction could phenocopy the results. Since bev-
acizumab and ranibizumab target human VEGF, we used a mono-
clonal antibody against murine VEGF that was validated prior to 
use (Supplemental Figure 3, A–C).
After administering a single dose of anti-VEGF intravitreally 
to adult mice, we confirmed reduction in retinal VEGF concentra-
tions (Figure 4A) and observed reduced retinal CFH 24 to 48 hours 
later (Figure 4B, in situ hybridization; control in Supplemental 
Figure 4A, C-qPCR, D-CFH ELISA) and reduced CFH in choroid/
RPE samples (Figure 4E, Western blot). We also used Western 
blotting to study retinal lysates and detected several bands that 
could represent CFH-related proteins (Supplemental Figure 4C). 
These bands were not detected in choroid/RPE lysates. Reduced 
retinal CFH was also seen after injection of commercially available 
aflibercept (Supplemental Figure 4D), but not after injection with 
PBS or control IgG1 (Supplemental Figure 4, A and D). Interesting-
ly, VEGF and CFH levels were also reduced in the kidneys of mice 
injected with intravitreal anti-VEGF 48 hours later (Supplemental 
Figure 5, A and B). VEGF and CFH concentrations measured in the 
same samples were correlated and showed a Pearson correlation 
coefficient of 0.94, indicating a strong correlation (Figure 4F). 
Retinal C3 was also increased 24 hours after injection (Figure 4G, 
in situ hybridization; control in Supplemental Figure 4B, H-qPCR). 
To directly assess complement activation in these mice, we mea-
sured C5b-9. This was significantly increased 48 hours after anti-
VEGF injection in WT mice, but not in C3-knockout mice (Figure 
4I). To validate these murine studies, aqueous humor from ARMD 
patients naive to anti-VEGF therapy was analyzed before and 48 
hours after a single injection of intravitreal bevacizumab. First, a 
significant reduction in VEGF was confirmed (Figure 4J). Next, 
complement activation was demonstrated with elevated C3a, 
C4a, and C5a levels (Figure 4, K–M). In this small patient group, a 
greater increase in C3a levels 48 hours after 1 intravitreal injection 
of bevacizumab correlated with an earlier time to recurrence of 
wet ARMD (Figure 4N). No differences in VEGF reduction (Figure 
4O) or in C4a or C5a levels were detected between these groups 
(Supplemental Figure 6, A –C).
After detecting the anaphylatoxins C3a, C4a, and C5a, which 
stimulate inflammation, we also measured proinflammatory cyto-
kines. IL-6 and IL-8 were also increased in these patient samples 
and primary human RPE cell culture supernatant and in murine 
retinae after intravitreal anti-mouse VEGF, but not control IgG1 
(Supplemental Figure 7, A–C). This was noteworthy because 
increased IL-6 and IL-8 have been associated with wet ARMD (37, 
38). Retinal inflammation was further demonstrated by Müller glia 
and microglia activation, while apoptotic cells were detected in 
the ganglion cell layer after a single intravitreal dose of anti-VEGF 
(Supplemental Figure 7, D–F). Aflibercept intravitreal injection pro-
duced similar effects. This demonstrates that a single dose of VEGF 
antagonist can induce complement activation and inflammation.
Complement pathway inhibition reduced anti-VEGF–induced 
endothelial cell activation. Since genetic ablation of RPE VEGF 
caused degeneration of the choriocapillaris, we studied the 
effect of intravitreal anti-VEGF on markers of endothelial cell 
activation. Murine eyes showed increased levels of serpine-1/ 
endothelial plasminogen activator inhibitor (PAI-1), P-selectin, and 
lectin-like oxidized LDL receptor (39) 24 to 48 hours after 1 anti-
VEGF injection (Figure 5, A–D). To determine whether comple-
ment activation contributed to this, mice lacking the complement- 
activating protein C3 were studied. These mice showed signifi-
cantly reduced markers of endothelial activation after intravitreal 
anti-VEGF compared with controls (Figure 5, A–D). This suggests 
that complement inhibition reduced endothelial cell activa-
tion that resulted from anti-VEGF injection. C3-knockout mice 
showed no difference in apoptosis, Müller glia, or microglia cell 
activation after VEGF antagonism (Supplemental Figure 7, D–F). 
Therefore, complement activation may be particularly important 
for anti-VEGF–associated endothelial cell changes.
CFH genetic variants caused more complement deposits, which 
were increased by VEGF antagonism. To study the effects of VEGF 
antagonism in patients with CFH genetic variants and how these 
Figure 4. Intravitreal anti-VEGF results in reduced CFH and complement activation. The retinas of mice injected with anti-mouse VEGF showed a signif-
icant reduction in VEGF protein after 48 hours (A, n = 4). This was associated with a reduction in CFH RNA, as shown by in situ hybridization (B, CFH red, 
DAPI blue, n = 8) and confirmed by qPCR (C, n = 6), CFH protein in the retina (D, n = 3), and choroid/RPE (E, 150 kDa band, n = 6). VEGF and CFH concentra-
tions measured in the same lysates showed significant correlation with a Pearson coefficient of 0.94 (95th CI 0.87–0.97) (F, n = 30). There was increased 
C3 RNA after a single anti-VEGF injection (G, n = 8). A linear C3 staining pattern in the in situ hybridization suggests that Müller cells may be a C3 source 
(C3 red, DAPI blue). A 200-fold increase in retinal C3 RNA was confirmed by qPCR (H, n = 6). WT mice injected with anti-VEGF also showed increased C5b-
9, indicating complement activation (I, n = 3). C3 knockout mice did not show this effect. The changes in RNA were detected after 24 hours, while protein 
changes were detected after 48 hours. Aqueous humor from 10 ARMD patient eyes was sampled before and 48 hours after a single intravitreal bevacizum-
ab. The samples obtained after injection showed reduced VEGF (J) and increased C3a (K), C4a (L), and C5a levels (M). Patients who had a recurrence of wet 
ARMD within 100 days of treatment (range 47–86 days, n = 6) had a greater rise in C3a 48 hours after intravitreal bevacizumab injection than patients who 
relapsed more than 100 days later (range 152–449days, n = 4) (N). There were no significant differences in VEGF (O). Human samples were analyzed by CBA 
or ELISA carried out in triplicate and analyzed using Mann-Whitney U test. Images represent 3 independent experiments. Scale bars: 100 μm. Unpaired, 
2-tailed t test (A, C, D, E, H, J–O); 1-way ANOVA (I). *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 2). However, there was significantly (Figure 6A, asterisks) 
more C3d on the ARMD cells after bevacizumab compared with 
untreated ARMD cells, suggesting that the effects of VEGF antag-
onism on complement inhibitor expression further reduced the 
complement regulatory capacity of the ARMD cells. Treatment with 
aflibercept showed comparable results (Supplemental Figure 8, C 
and D). Similar results were also obtained in human aHUS podocytes 
expressing Arg1182Ser CFH mutation that affects CFH cell-surface 
binding (40) (Figure 6, C and D and Supplemental Figure 8E). This 
suggests that ARMD RPE and aHUS podocytes are less efficient at 
inhibiting the alternative pathway at the cell surface and so could be 
more susceptible to reduction of CFH and other complement inhib-
itors mediated by VEGF antagonism. This may explain why patients 
with CFH genetic variants are at greater risk of ARMD and HUS and 
could have implications for patients receiving anti-VEGF therapy.
Discussion
For the first time, to our knowledge, we report a link between local 
VEGF availability and complement inhibition in the retina and 
renal glomerulus that is mediated by changes in local comple-
may alter complement cell-surface regulation, we studied RPE that 
carried the ARMD-associated CFH 402H polymorphism (ARMD 
RPE) and podocytes from an aHUS patient carrying a known CFH 
mutation (Arg1182Ser) (aHUS podocytes) (40). First, we measured 
CFH production by these cells at baseline and after treatment with 
VEGF, bevacizumab, or aflibercept and correlated this with VEGF 
concentration in serum-free conditioned media (Supplemental Fig-
ure 8, A and B). A strong correlation between CFH and VEGF was 
found in both induced pluripotent stem cells (iPS cells) RPE (Supple-
mental Figure 8A, r = 0.86) and podocytes (Supplemental Figure 8B, 
r = 0.87). Next, functional complement studies were performed. 
Without treatment, ARMD RPE showed significantly more C3d 
deposits compared with controls (Figure 6A), but there were no 
significant differences in C4d deposits (Figure 6B). This suggests 
increased activation of the alternative pathway, but no difference 
in classical pathway regulation on the surface of these ARMD cells 
that possess the CFH polymorphism. Bevacizumab significantly 
increased C3d and C4d deposits in both cell lines, while VEGF treat-
ment reduced both (Figure 6, A and B-hatch marks). This confirmed 
our previous results using primary human RPE cells (Supplemental 
Figure 5. Intravitreal anti-VEGF causes endothe-
lial activation, but this is reduced by comple-
ment inhibition. Evidence of endothelial cell 
activation was detected 24 hours after a single 
dose of intravitreal anti-mouse VEGF, as shown 
by an increase in PAI-1/serpine 1 (A), P-selectin 
(B), and oxidized low density lipoprotein receptor 
1 (Lox1) (C) in WT mice. Complement C3 knockout 
mice showed significantly less PAI-1, P-selectin, 
and Lox1 after intravitreal anti-VEGF when com-
pared with WT mice (A, B, C, comparison shown 
by black bar). Lox 1 protein was also increased on 
Western blot 48 hours after single intravitreal 
injection of anti-VEGF (D, first 2 columns), but 
this increase was significantly less in C3 knock-
out mice at the same time point when compared 
with WT mice (D, WT anti-VEGF vs. C3KO 
anti-VEGF). This suggests that complement 
inhibition may reduce levels of endothelial cell 
activation after anti-VEGF injection. n = 4–6 mice 
per condition. qPCR run in triplicate. One-way 
ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001;  
#P < 0.05; ####P < 0.0001. Asterisks show sta-
tistics comparing the anti VEGF effect between 
wild type and C3 KO mice. The hatch marks show 
statistics comparing wild type mice only (IgG1 
control vs anti VEGF) or C3 ko mice only (IgG1 
control vs anti VEGF).
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ARMD is a multifactorial disease. Aging is the primary risk 
factor, but genetic susceptibility and environmental exposures 
influence disease acquisition (1). Complement gene mutations 
confer risk (1), but it is unclear precisely how they contribute to 
ment inhibitor expression (Figure 7). This provides insight into the 
underlying pathogenesis of ARMD and HUS as well as providing a 
possible explanation for the adverse effects associated with VEGF 
antagonism in both organs.
Figure 6. CFH genetic variants are less effective at regulating the alternative complement pathway. Human iPS cells differentiated to RPE containing 
the ARMD CFH 402H polymorphism (ARMD cells) showed greater C3d deposits (C3d white, DAPI blue) compared with control cells when complement 
was activated on the cell surface (A, media, untreated column comparison). This effect was exacerbated by bevacizumab treatment (A, bevacizumab 
column comparison). There was no difference between cell types when C4d staining was analyzed at baseline without treatment or after bevacizumab 
(B, black lines denote comparison, C4d white, DAPI blue). However, bevacizumab significantly increased C4d deposits, and VEGF reduced these on both 
cell lines. The same effect was seen in podocytes after treatment with VEGF and bevacizumab for C3d (C, C3d white, DAPI blue) and C4d (D, C4d white, 
DAPI blue). Representative images from 4 independent experiments. Ten images obtained for each condition per individual experiment. Fluorescence 
was measured as MFI and corrected for cell number (semi-quantitative assessment). Two-way ANOVA. Statistics comparing the same cell types exposed 
to different treatments denoted as hatch marks. Statistics comparing different cell types denoted as NS or asterisks. #P < 0.05; ##P < 0.01; ###P < 0.001; 
*P < 0.05; ***P < 0.001; ****P < 0.0001. Black bars show which conditions were compared. Scale bars: 200 μm
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Complement activation may also affect the choroidal vas-
culature (50). Our studies showed that inhibiting complement 
partially prevented the anti-VEGF–induced increase in endothe-
lial cell activation, suggesting that complement inhibition could 
protect the endothelium. Previously, animal models showed that 
alternative pathway activation contributes to the development 
of CNV (51, 52), while cell culture studies revealed that sublytic 
levels of MAC can increase RPE-derived VEGF (44), which could 
contribute to the development of CNV. Considering these data, 
early complement inhibition in ARMD may prevent some of these 
negative effects and could reduce the abnormal increase in secret-
ed RPE-derived VEGF. However, a balance must be struck, since 
murine studies also suggest that complete, prolonged complement 
inhibition is detrimental (53). Further work is needed to examine 
this, particularly in humans, since there are important species 
differences in the complement cascade. Complement inhibition 
in ARMD, including GA, is an area of active study, with several 
agents currently in phase 2/3 trials (54).
Complement protein mutations are also associated with glo-
merular TMA, as shown by studies of familial aHUS (55). The 
same glomerular pathology was later identified in patients receiv-
ing systemic bevacizumab to treat tumor angiogenesis (56, 57). 
Eremina et al. showed that these effects were replicated in mice 
with a glomerular-specific VEGF knockout (29), highlighting the 
importance of local podocyte-derived VEGF in the maintenance 
of the glomerular endothelium. Using the same model and human 
cells in vitro, we show that reduced glomerular VEGF decreased 
expression of local CFH and other complement regulators in both 
podocytes and glomerular endothelial cells, predisposing them 
to complement deposition. These findings link the pathogenesis 
of glomerular TMA associated with anti-VEGF therapy to that 
of complement-mediated aHUS and may explain why the renal 
glomerulus is susceptible to complement-mediated disease. Inter-
estingly, preeclampsia, another glomerular disease associated 
ARMD pathogenesis. The most widely studied is the CFH 402H 
polymorphism, and we demonstrated that RPE cells with this poly-
morphism showed more cell-surface complement deposition. This 
supports previous studies that showed CFH 402H does not effec-
tively bind to the cell-surface glycosaminoglycan heparan sulphate 
and this can affect surface complement regulation (24, 41, 42). In 
the kidney, several aHUS CFH mutations also affect the protein’s 
ability to bind to the cell surface and regulate complement (43). 
Therefore, we compared an aHUS podocyte cell line with a known 
CFH mutation (40) to the ARMD RPE cells with the CFH polymor-
phism in our complement activation assay and obtained similar 
results, suggesting that the effect observed in RPE cells could be 
due to impaired cell-surface binding of CFH 402H. Formal binding 
studies would be needed to confirm these results.
Complement activation is a known feature of ARMD (21, 23, 
24, 44), and our experiments suggest VEGF antagonism could 
exacerbate this by reducing synthesis of CFH and other inhib-
itory complement proteins. Since both C3 and C4 deposits were 
increased by VEGF antagonism, these effects likely represent 
changes in multiple complement inhibitors simultaneously. These 
effects were more pronounced in cells expressing CFH 402H, pos-
sibly because they already have reduced complement regulatory 
capacity and anti-VEGF treatment could decrease this further. 
This could explain why the CFH 402H polymorphism has been 
reported to correlate with a reduced response to anti-VEGF ther-
apy (19, 45, 46), although in this complex disease, it is likely that 
several other factors also contribute to the variable response to 
anti-VEGF therapy (47). Furthermore, while controversial, there 
are patient studies suggesting that VEGF antagonists may enhance 
progression of GA (8, 9, 48, 49), which could be related to direct 
complement-mediated damage of the RPE cells. Importantly, this 
does not affect every patient and more work is needed to identify 
those at risk, but homozygosity of the CFH 402H polymorphism 
may be one factor.
Figure 7. Proposed model of how VEGF 
regulates local complement activity. (A) 
Under normal circumstances in the outer 
retina and renal glomerulus, specialized 
epithelial cells (the RPE and podocytes, 
respectively) produce VEGF that has both 
autocrine effects and paracrine effects on 
neighboring endothelial cells. VEGF sig-
naling through VEGFR2 causes inhibitory 
complement proteins such as CFH to be 
produced by these cells. These comple-
ment inhibitors function at the cell surface 
to prevent complement activation caused 
by spontaneous alternative pathway 
hydrolysis. In the case of CFH, this occurs 
by binding to the cellular glycocalyx and 
acting as a cofactor for factor I (FI). (B) 
When anti-VEGF therapy is given, there 
is reduced local VEGF production, which 
leads to less VEGFR2 signaling. This may 
cause a reduction in local complement 
inhibitor synthesis and secretion, making 
the cells more vulnerable to complement 
activation.
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Therefore, documentation of renal function, blood pressure, and 
urinalysis before and during treatment with anti-VEGF agents 
would be prudent, particularly in ARMD patients who have renal 
comorbidities. From our results, patients carrying CFH genetic 
variants may also be more sensitive to VEGF antagonism. The 
ARMD CFH 402H polymorphism has been associated with mem-
branoproliferative glomerulonephritis (43), which could indicate 
that the kidneys of these patients are more vulnerable to comple-
ment activation as well. To confirm these findings, a larger study 
detailing genotype/phenotype correlations of renal and retinal 
function before and after VEGF antagonism would be beneficial 
to identify factors that predispose patients to developing these 
adverse effects. This could potentially guide an individualized 
approach to therapy in the future. In the meantime, our findings 
suggest that side-effect monitoring should be more rigorous. 
Assessment of glomerular function by monitoring for proteinuria, 
hypertension, and reduced renal function could be particularly 
important for patients with preexisting renal disease or a CFH 
genetic variant receiving anti-VEGF therapy. In ARMD, documen-
tation of visual acuity and GA before and, at regular intervals, after 
initiation of VEGF antagonism may help guide therapy, including 
determining whether it should be continued or stopped. With 
increasing use of VEGF antagonists, all clinicians should be aware 
of the potential adverse effects and be vigilant to aid detection and 
prevent unnecessary morbidity.
Methods
Additional supplemental methods used are detailed in the supple-
mental materials.
Human samples. After written informed consent, 10 ARMD 
patient eyes naive to anti-VEGF therapy had aqueous humor sampled 
before intravitreal bevacizumab injection (1.25 mg) and 48 hours later 
by Yoshihiro Wakabayashi or Yasuyuki Yamauchi (Tokyo Medical Uni-
versity Hospital). Eight patients were studied, 5 male and 3 female, 
with an average age of 71.1 ± 3.2 years. All had typical ARMD diag-
nosed after fundus examination with a fluorescein angiography, indo-
cyanine green angiography, and optical coherence tomography. Wet 
ARMD was diagnosed according to established criteria (77). The eyes 
studied showed classic CNV (2/10), minimally classic CNV (1/10), 
and occult CNV (7/10), but no retinal angiomatous proliferation. 
Patients with cataracts causing moderate-to-severe visual disturbance 
received elective surgery 2 days after intravitreal bevacizumab. Aque-
ous humor was collected before surgery for evaluation after injection. 
Samples were immediately frozen and stored at –80°C until analyzed. 
Recurrence was defined by fluorescein angiography (recurrence of 
leakage and leakage from new vessels at the site of previous lesions), 
indocyanine green angiography (recurrence of leakage), OCT (fluid in 
OCT and increase of macular thickness in OCT with visual loss), and 
clinical findings (new macular hemorrhages, new classic CNV) during 
the follow-up examinations, as previously described (78).
Mice. Kidneys from podocyte-specific tetracycline-inducible 
Vegfa-knockout mice (29), aged 3 to 4 weeks (supplied by Susan 
Quaggin, [Northwestern University, Chicago, Illinois, USA] and Vera 
Eremina [Samuel Lunenfeld Research Institute, Toronto, Canada]), 
were obtained 14 days after oral induction using 0.2% doxycycline. 
During this time, mice were monitored for proteinuria alongside 
noninduced littermate controls.
with endotheliosis and caused by chronic VEGF inhibition sec-
ondary to increased soluble VEGFR1, is also associated with com-
plement activation (58, 59), suggesting that this work may also be 
relevant to this disease.
Glomerular TMA also occurs after administration of receptor 
tyrosine kinase inhibitors such as sunitinib that block VEGFR2 (57, 
60) and in mice with reduced endothelial cell VEGFR2 expres-
sion (61), suggesting that anti-VEGF–associated TMA results from 
decreased VEGFR2 signaling. Building on this, we show that inhib-
iting PKC blocked the VEGF-induced CFH increase. This was con-
firmed with CRISPR knockout studies targeting PKC-α and CREB. 
This is not the first time these pathways have been implicated 
in complement protein regulation. While CFH was not studied, 
Mason et al. showed that HUVECs and dermal endothelial cells 
expressed more CD55, but not CD46 or CD59, after VEGF treat-
ment (62). This was mediated by PKC-CREB signaling (63). In our 
study, HUVECs exhibited a different response to VEGF-induced 
CFH expression compared with glomerular endothelial cells. Con-
versely, the glomerular endothelial cells did not show an increase 
in CD55 after VEGF treatment, but CD46 and CD59 were both 
increased along with CFH. This could indicate a heterogeneous 
endothelial response to VEGF and complement protein expression 
that varies between different vascular beds. While further work is 
needed to examine this in more detail, previous studies showed 
different isoforms of PKC can produce differential effects in endo-
thelial cells (64). However, VEGF/VEGFR2 signaling is complex 
(34) and there are several other points at which modulation could 
occur: (a) interactions between receptor and coreceptors such as 
the neuropilins (34, 65) or extracellular matrix molecules such as 
integrins (66) or the cellular glycocalyx (67); (b) receptor inter-
nalization, recycling, and degradation may also be important (65, 
68, 69); and (c) differential phosphorylation could occur second-
ary to the availability of adapter and scaffolding proteins as well 
as phosphatases such as PTP1B (65, 69). Furthermore, there are 
several ways CREB phosphorylation can be modified (70). These 
processes could explain the differential effects of VEGF at differ-
ent sites around the body, but an extensive systematic study would 
be needed to tease out the details.
VEGF antagonists are widely used to treat not only ARMD but 
also cancers and other diseases associated with retinal neovascu-
larization, including proliferative diabetic retinopathy, retinal vein 
occlusion (71), and, “off label,” for retinopathy of prematurity (72). 
Intravitreal doses are smaller than systemic ones and thus would 
be expected to cause fewer adverse effects. However, the drugs 
are systemically cleared and can suppress circulating VEGF lev-
els (73). We found reduced VEGF and CFH levels in murine kid-
neys 48 hours after intravitreal injection. This confirmed primate 
studies that detected anti-VEGF agents in glomeruli one day after 
intravitreal injection (74). Furthermore, glomerular dysfunction 
has been reported for all intravitreal VEGF antagonists currently 
used in patients (75, 76). Not all patients are affected, but preexist-
ing renal pathology may increase susceptibility. Recently, 2 renal 
transplant patients were reported to have developed antibody- 
mediated rejection after intravitreal therapy for ARMD (75). 
Another study reported diabetic patients with nephropathy and 
retinopathy whose renal function deteriorated from stage IV to 
stage V chronic kidney disease after intravitreal anti-VEGF (76). 
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iPS cells differentiated into RPE were supplied by K. Bharti. The 
human iPS cells were derived and differentiated to RPE as described 
(84). Cells were genotyped for the CFH Y402H polymorphism 
(rs1061170, T1277C). Two cell lines were used, one with the normal 
402Y allele and one with the ARMD-associated 402H allele. They were 
maintained in knockout DMEM with 1% glutamate, nonessential amino 
acids, penicillin and streptomycin, 0.18% β mercaptoethanol, 10 ng/ml 
basic FGF, and 20% knockout serum replacement (Life Technologies).
Cell treatments. Cells grown in serum-containing media were 
serum starved for 1 to 2 hours prior to treatment with VEGF-165 (0.1 
ng/ml-100ng/ml, R&D Systems), bevacizumab (250 μg/ml), ranibi-
zumab (125 μg/ml) (both from Genentech), aflibercept (500 μg/ml, 
Regeneron), inhibitors, or activators in serum-free media. Wortman-
nin (0.5 μM) (W1628-PI3Kinase inhibitor), H-89 (20 μM) (B1427-PKA 
inhibitor), U0126 (10 μM) (U0120-MEK inhibitor), SB202190 (20 
μM) (S7067-p38 MAPK inhibitor), GF109203X hydrochloride (20 nM) 
(B6292-PKC inhibitor), forskolin (50 μM) (F6886-PKA/adenylate 
cyclase activator), and PMA (80 nM) (P1585-PKC activator) were pur-
chased from Sigma-Aldrich.
Knockout podocyte cell lines. PKC-α– and CREB-disrupted podo-
cytes were generated using CRISPR/Cas9 to target the PRKCA gene 
and CREB1 gene in immortalized human podocytes. A guide RNA 
targeting the translated region of PRKCA exon 1 (CAACGACTCCAC-
GGCGTCTC) or CREB 1 exon 2 (GGAGCCGAGAACCAGCAGAG) 
was ligated into the LentiGuide Puro vector (85) and confirmed by 
Sanger sequencing. Virus was generated by cotransfection of vector, 
pMDG2, and psPAX2 in HEK293T cells and used to infect a podo-
cyte line that stably expressed Cas9 endonuclease. Cells were select-
ed with puromycin. Successful CRISPR gene editing was confirmed 
by Sanger sequencing with primers for PRKCA exon 1 coding region 
(CCDS11664.1, forward, CACCGGGCTGTCAGTGAG, reverse, 
CGGTTCCAAGTTATCGGAGT) or CREB1 exon 1 (CCDS2374.1, 
forward, ACCACTGCACCTCTCCTTGT, reverse, TTCTGGAT-
CATTTCACTAAAAAT).
qPCR. RNA was isolated using TRIzol/chloroform extraction as 
described (86) or using the QIAGEN miRNeasy Mini Kit according 
to the manufacturer’s instructions. Cells were treated for 4 hours 
and experiments repeated 3 times. Mouse eyes were extracted and 
the retina separated from the choroid/RPE. From 2 to 3 animals per 
condition were studied in individual experiments, and these were 
repeated 3 times. Complementary DNA was made using the High- 
Capacity RNA to cDNA Kit (Life Technologies) or the QuantiTect 
Reverse Transcription Kit (QIAGEN). SYBR Green (Sigma-Aldrich) 
primer sequences are detailed in the Supplemental Table 1 (Life 
Technologies). SYBR Green reaction mix was used (Sigma-Aldrich) 
on the StepOnePlus Real-Time PCR system (Applied Biosystems) or 
the CFX 96 (Bio-Rad). TaqMan qPCR was performed on the Bio-Rad 
CFX 96 using murine primers (Supplemental Table 2, Life Technol-
ogies). Each reaction was run in triplicate. Relative expression was 
determined compared with GAPDH or actin controls. Changes in 
mRNA expression in treated cells relative to respective controls were 
then calculated using the ΔΔCT method.
ISH. The Affymetrix QuantiGene View RNA ISH system was 
used according to the manufacturer’s instructions. Briefly, tissue was 
dissected and fixed in 4% PFA for 6 hours for eyes and 24 hours for 
solid organs. Sections were further fixed in 4% formaldehyde at 4°C 
for 16 hours prior to ISH. Protease solution was applied to eyes (1:25 
Retinal Vegfa knockout was achieved in RPE cells using tetracy-
cline inducible VMD2 Cre (4) (Yung-Zheng Le, University of Oklaho-
ma, Oklahoma City, Oklahoma, USA) and in amacrine and horizontal 
cells using Ptf1a Cre (Jackson Laboratories) (10). Floxed gene ablation 
was induced in 4-week-old VMD2-Cre Vegfa or Vhl floxed mice (Jack-
son Laboratories) by administering 80 μg/g body weight doxycycline 
intraperitoneally for 3 consecutive days as described (4). Eyes were 
analyzed 3 days after induction. Ptf1a is expressed in the retina from 
E12.5 (10), and mice were analyzed on postnatal day 18.
The number of mice required for each experiment was deter-
mined as described (79) based on a power of 80% and P = 0.05. For 
all studies, equal numbers of males and females were included in 
each group. No formal randomization was undertaken. Outliers were 
identified and removed if they were more than 3 SD from the mean.
Intravitreal murine injections. Anti-mouse and human VEGF B20 
biosimilar was made according to the published sequence of B20-4.1 
(80). The variable region of the heavy and light chains of B20-4.1 was 
fused to the constant region of IgG1 and k chain, respectively. Sta-
ble mammalian 293 cell lines for recombinant B20 production were 
established using the piggyBac transposon system (81). Briefly, the 2 
genes encoding for the heavy and light chains were cloned into 2 dif-
ferent PB-T-RfA transposons, and we used a 1:2 ratio of heavy to light 
chain during transfection. Recombinant B20 was purified using pro-
tein A affinity column, and stored in 50 mM sodium phosphate buffer 
containing 150 mM NaCl (pH 7.0).
Adult C57BL/6 mice or complement C3 knockout mice (Jackson 
Laboratories) were anesthetized using 15 mg/kg ketamine and 7 mg/
kg xylazine administered intraperitoneally prior to 0.5 μl intravitreal 
injection of 5 mg/ml anti-murine VEGF (B20), control murine IgG1 
(R&D Systems), aflibercept (Regeneron Pharmaceuticals), or control 
human IgG1 (R&D Systems). PBS-injected and uninjected eyes served 
as further controls. Eyes were extracted at 24 or 48 hours to analyze 
RNA or protein, respectively. Four to six eyes per condition were ana-
lyzed with 3 different litters used per experiment.
Cell culture. Human conditionally immortalized glomerular 
endothelial cells and podocytes transfected with temperature- 
sensitive SV40 were used as described (Satchell et al., ref. 82; Sal-
eem, et al., ref. 83). Podocyte cells were also obtained from an aHUS 
patient with an Arg1182Ser (G3546T) CFH mutation, which affects 
the ability of CFH to bind to heparin and C3b (40). Immortalized 
cells were grown in humidity with 5% CO2 at the permissive tem-
perature of 33°C until 80% confluent, then thermo-switched to 37°C 
for 4 to 5 days for glomerular endothelial cells (GEnC) and 12 to 14 
days for podocytes to “switch off ” SV40 expression and facilitate 
differentiation. Podocytes were grown in RPMI-1640 with 10% FBS 
supplemented with 1% insulin, transferrin, and selenium. GEnC 
were grown in EGM-2MV media with 5% FBS supplemented with 
human EGF (hEGF), hydrocortisone, gentamicin, amphotericin, 
human FGF-B (hFGF-B), IGF-1, and ascorbic acid (EGM-2MV Bull-
etKit except VEGF, Lonza).
ARPE19 cells (Life Technologies), human primary RPE cells 
(Lonza), HUVEC cells (Lonza), and HEK293 cells (ATCC) were grown 
at 37°C in humidity with 5% CO2. AREP19 were maintained in DMEM 
F12 with 2% FBS. HRPE cells were grown in RPE cell basal media 
(RtEBM) with BulletKit (Lonza). HUVEC cells were grown in EGM2 
media with 5% FBS and added BulletKit (Lonza). HEK293 cells were 
maintained in RPMI 1640 with 5% FBS.
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a HCX PL FLUOTAR L 40 × 0.6 objective lens with an optical zoom 
of 40 or 20×/0.8 Dry Plan-Apochromat. Images were taken blind-
ly with only 1 control slide labeled. Microscope settings were deter-
mined using a control slide and the brightest staining slide for each 
experiment. They were then maintained for all remaining compara-
tive slides. Image analysis was carried out using ImageJ (NIH). For all 
raw images, mean fluorescence intensity (MFI) values were calculated 
and corrected for cell number determined by DAPI nuclear stain to 
allow semi-quantitative analysis of immunofluorescence (IF). Eight 
images per condition were analyzed from 4 independent experiments. 
For renal tissue, MFI was calculated for individual glomeruli and was 
corrected for cell number after counting DAPI-stained nuclei. These 
values were further corrected by subtracting background fluorescence 
intensity. Analysis incorporated 15 to 20 glomeruli per mouse from 3 
different sections. At least 8 mice per condition were analyzed from 4 
independent experiments. These studies were based on the use of IF 
and quantification by others (43, 88, 89). More details on antibodies 
used are given in Supplemental Table 3 and 4. For retinal sections, the 
number of positive cells was counted and corrected for retinal length 
(mm) from 3 different sections per eye.
Factor H resynthesis assay. Cells were grown for IF. Once differ-
entiated, they were washed in PBS and treated with 0.1 M acetic 
acid (Sigma-Aldrich) for 30 minutes at 37°C (90). After washing, 
cells were treated with VEGF, bevacizumab, ranibizumab, afilber-
cept, or inhibitors in serum-free media for 24 hours or immediate-
ly fixed in 4% PFA. Fixed, untreated cells were also used as con-
trols. CFH cell-surface expression was assessed according to the 
IF protocol described above. Images were analyzed as described. 
Ten images were obtained per condition for each experiment, and 
experiments were repeated 4 times.
Complement challenge assay. Cells grown for IF were incubat-
ed with 40% rabbit serum for 30 minutes at 37°C to establish cell- 
surface antigen-antibody complexes and then washed in PBS. The 
classical and alternative complement pathways were activated by add-
ing 30% human C7 deficient (C7d) serum (Quidel) diluted in gelatin 
veronal buffer (GVB2+, Sigma-Aldrich) for 30 minutes at 37°C. Heat- 
inactivated normal human serum and GVB buffer alone were used 
as controls. The absence of protein C7 meant that MAC did not form, 
and so cells remained intact. Complement activation was indirectly 
assessed using mouse anti-human antibodies against C3d and C4d 
(Quidel, Supplemental Table 3). These markers were used to assess 
complement activation because C3b and C4b are degraded in the 
presence of serum-based proteases such as factor I (91). These degra-
dation products covalently bind to cells and tissue and persist for hours 
after complement activation. Their use was previously validated (92). 
Primary antibodies were applied for 60 minutes at room temperature 
after PFA fixation followed by secondary antibody (Life Technologies) 
applied for 1 hour at room temperature. Quantification was performed 
as for IF using ImageJ (NIH). Ten images per condition were obtained 
per experiment, and 4 independent repeats were performed.
Statistics. Statistical analyses were carried out using PRISM 
(version 6, GraphPad Software). Experiments involving 2 groups 
were compared using unpaired, 2-tailed t tests except analysis 
of aqueous humor, for which paired, 2-tailed t tests were used. 
Mann-Whitney U test was used to compare time to recurrence data 
from ARMD patients. Multiple comparisons were made using 1-way 
ANOVA with Bonferroni’s post hoc analysis. Two-way ANOVA with 
dilution) for 10 minutes and for solid organs (1:100) for 20 minutes at 
40°C. Probes for murine VEGF (VB1-16139 and VB6-12843), murine 
C3 (VB1-13781), human VEGF (VA1-16136), and human CFH (VA6-
16509) were used. Murine CFH was designed and made by Affymet-
rix using the accession number NM_009888.3 (VB1-16095). Fluores-
cent detection was used to analyze the ISH with DAPI nuclear costain. 
Eight mice per condition were analyzed for each experiment. Samples 
were collected from 3 independent experiments.
Cytometric bead array. Human C3a and C4a were examined 
using the BD Human Anaphylatoxin Cytometric Bead Array (CBA) 
Kit. Aqueous humor samples were analyzed at 1:5 dilution. Cyto-
kines including VEGF, MIP-1B, MCP1, IL-6, and IL-8 were mea-
sured using the BD CBA Flex Immunoassay Kit (BD) as described 
(87). A list of all other cytokines analyzed using this assay is given in 
the Supplemental Methods.
ELISA. Human C5a was measured in aqueous humor using the 
Quidel MicroVue C5a EIA (A021) according to the manufacturer’s 
instructions. Human CFH was measured in conditioned media using 
an AbCam ELISA (ab137975). Murine CFH was measured using a 
LifeSpan BioScience ELISA (LS-F4381). Murine C5b-9 was measured 
using a myBioSource ELISA (MBS703522). All samples were analyzed 
in duplicate. The plates were imaged at 450 nm and 570 nm to cor-
rect for nonspecific signal, using a BioTek Synergy 2 plate reader. Data 
were analyzed using Gen5 BioTek software.
Western blotting. Lysates were made using RIPA lysis buffer with 1% 
phosphatase and protease inhibitors (Sigma-Aldrich). Protein concen-
tration was measured by BCA assay (Thermo Scientific). Samples were 
resolved on 10% SDS-PAGE or 4%–12% gradient NuPage Bis-Tris gel 
(Life Technologies) under reducing conditions and blotted onto polyvi-
nylidene fluoride or nitrocellulose (Immobilon-p, Immobilon-Fl, Nitro-
cellulose-Fl, Millipore). Membranes were blocked in Licor blocking 
buffer, 5% BSA, or skim milk. Primary antibodies were incubated over-
night at 4°C (Supplemental Table 3). Blots were subsequently washed in 
TBST and incubated with secondary antibody (Supplemental Table 4). 
For fluorescent Western blots, the Licor Odyssey Fc was used to detect 
bands. Alternatively, an ECL chemiluminescence system (Amersham 
Biotech) was used and images acquired using a ChemiDoc-It imager 
(UVP). Densitometry was performed using Quantity One software 
(v4.6.5, Bio-Rad Laboratories) or ImageJ (NIH).
Meso scale discovery. Protein concentrations were also measured 
using meso scale discovery (MSD) technology per the manufactur-
er’s instructions. Murine samples were analyzed using the V-plex 
proinflammatory panel 1 kit (K15048D) or the U-plex VEGF assay 
(K152UVK). Human condition media samples were analyzed using the 
V-plex human VEGF kit (K151RHD).
Immunofluorescence. Cells were grown and differentiated on either 
glass coverslips or chamber slides in serum-containing media. After 
treatment, cells were fixed in 4% PFA (Sigma-Aldrich) and blocked 
in 5% BSA. Fresh-frozen sections were fixed in 4% PFA and blocked 
in 10% goat or donkey serum with 3% BSA and 0.1% Triton X-100 
in PBS. Primary antibodies were incubated overnight at 4°C before 1 
hour of incubation with secondary antibodies (Supplemental Table 3 
and 4) at room temperature, followed by DAPI nuclear stain. Samples 
were mounted with Slowfade Gold Anti-Fade Mount (Life Technolo-
gies) prior to imaging using the Leica DMI 6000B microscope, Leica 
confocal imaging spectrophotometer system (TCS-SP2), or the Zeiss 
LSM 700 or 710. Imaging was carried out at room temperature with 
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